These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 21506111

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Unique antineoplastic profile of Saquinavir-NO, a novel NO-derivative of the protease inhibitor Saquinavir, on the in vitro and in vivo tumor formation of A375 human melanoma cells.
    Donia M, Mangano K, Fagone P, De Pasquale R, Dinotta F, Coco M, Padron J, Al-Abed Y, Giovanni Lombardo GA, Maksimovic-Ivanic D, Mijatovic S, Zocca MB, Perciavalle V, Stosic-Grujicic S, Nicoletti F.
    Oncol Rep; 2012 Aug; 28(2):682-8. PubMed ID: 22665020
    [Abstract] [Full Text] [Related]

  • 3. Saquinavir-NO-targeted S6 protein mediates sensitivity of androgen-dependent prostate cancer cells to TRAIL.
    Mojic M, Mijatovic S, Maksimovic-Ivanic D, Dinic S, Grdovic N, Miljkovic D, Stosic-Grujicic S, Tumino S, Fagone P, Mangano K, Zocca MB, Al-Abed Y, McCubrey JA, Nicoletti F.
    Cell Cycle; 2012 Mar 15; 11(6):1174-82. PubMed ID: 22370480
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The antitumor properties of a nontoxic, nitric oxide-modified version of saquinavir are independent of Akt.
    Maksimovic-Ivanic D, Mijatovic S, Miljkovic D, Harhaji-Trajkovic L, Timotijevic G, Mojic M, Dabideen D, Cheng KF, McCubrey JA, Mangano K, Al-Abed Y, Libra M, Garotta G, Stosic-Grujicic S, Nicoletti F.
    Mol Cancer Ther; 2009 May 15; 8(5):1169-78. PubMed ID: 19417156
    [Abstract] [Full Text] [Related]

  • 6. Therapeutic potential of nitric oxide-modified drugs in colon cancer cells.
    Mojic M, Mijatovic S, Maksimovic-Ivanic D, Miljkovic D, Stosic-Grujicic S, Stankovic M, Mangano K, Travali S, Donia M, Fagone P, Zocca MB, Al-Abed Y, McCubrey JA, Nicoletti F.
    Mol Pharmacol; 2012 Oct 15; 82(4):700-10. PubMed ID: 22798453
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cathepsin E enhances anticancer activity of doxorubicin on human prostate cancer cells showing resistance to TRAIL-mediated apoptosis.
    Yasukochi A, Kawakubo T, Nakamura S, Yamamoto K.
    Biol Chem; 2010 Aug 15; 391(8):947-58. PubMed ID: 20482316
    [Abstract] [Full Text] [Related]

  • 10. Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels.
    Lu M, Strohecker A, Chen F, Kwan T, Bosman J, Jordan VC, Cryns VL.
    Clin Cancer Res; 2008 May 15; 14(10):3168-76. PubMed ID: 18483385
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. TRAIL apoptosis is enhanced by quercetin through Akt dephosphorylation.
    Kim YH, Lee YJ.
    J Cell Biochem; 2007 Mar 01; 100(4):998-1009. PubMed ID: 17031854
    [Abstract] [Full Text] [Related]

  • 14. Cationic liposome-mediated nitric oxide synthase gene therapy enhances the antitumor effects of cisplatin in lung cancer.
    Ye S, Yang W, Wang Y, Ou W, Ma Q, Yu C, Ren J, Zhong G, Shi H, Yuan Z, Su X, Zhu W.
    Int J Mol Med; 2013 Jan 01; 31(1):33-42. PubMed ID: 23128378
    [Abstract] [Full Text] [Related]

  • 15. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
    Liu X, Yue P, Chen S, Hu L, Lonial S, Khuri FR, Sun SY.
    Cancer Res; 2007 May 15; 67(10):4981-8. PubMed ID: 17510429
    [Abstract] [Full Text] [Related]

  • 16. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
    Zhang XD, Wu JJ, Gillespie S, Borrow J, Hersey P.
    Clin Cancer Res; 2006 Feb 15; 12(4):1355-64. PubMed ID: 16489094
    [Abstract] [Full Text] [Related]

  • 17. Antiapoptotic role of endogenous nitric oxide in human melanoma cells.
    Salvucci O, Carsana M, Bersani I, Tragni G, Anichini A.
    Cancer Res; 2001 Jan 01; 61(1):318-26. PubMed ID: 11196180
    [Abstract] [Full Text] [Related]

  • 18. CHM-1 induces apoptosis via p38-mediated upregulation of DR5 expression in human ovarian cancer SKOV3 cells.
    Lee JC, Chou LC, Huang CH, Chung JG, Huang LJ, Lee KH, Hung MC, Way TD, Kuo SC.
    Eur J Pharmacol; 2011 Nov 16; 670(1):96-104. PubMed ID: 21907193
    [Abstract] [Full Text] [Related]

  • 19. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
    Itashiki Y, Harada K, Ferdous T, Yoshida H.
    Anticancer Res; 2007 Nov 16; 27(4B):2365-75. PubMed ID: 17695527
    [Abstract] [Full Text] [Related]

  • 20. Withaferin A inhibits iNOS expression and nitric oxide production by Akt inactivation and down-regulating LPS-induced activity of NF-kappaB in RAW 264.7 cells.
    Oh JH, Lee TJ, Park JW, Kwon TK.
    Eur J Pharmacol; 2008 Dec 03; 599(1-3):11-7. PubMed ID: 18838070
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.